Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral cancer

Abstract

Radiotherapy is one of the most common treatments for oral cancer. However, in the clinic, recurrence and metastasis of oral cancer occur after radiotherapy, and the underlying mechanism remains unclear. Cancer stem cells (CSCs), considered the “seeds” of cancer, have been confirmed to be in a quiescent state in most established tumours, with their innate radioresistance helping them survive more easily when exposed to radiation than differentiated cancer cells. There is increasing evidence that CSCs play an important role in recurrence and metastasis post-radiotherapy in many cancers. However, little is known about how oral CSCs cause tumour recurrence and metastasis post-radiotherapy. In this review article, we will first summarise methods for the identification of oral CSCs and then focus on the characteristics of a CSC subpopulation induced by radiation, hereafter referred to as “awakened” CSCs, to highlight their response to radiotherapy and potential role in tumour recurrence and metastasis post-radiotherapy as well as potential therapeutics targeting CSCs. In addition, we explore potential therapeutic strategies targeting these “awakened” CSCs to solve the serious clinical challenges of recurrence and metastasis in oral cancer after radiotherapy.

References

[1] Bray F, . Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68: 394-424.

[2] Shahinas J, Hysi D. Methods and risk of bias in molecular marker prognosis studies in oral squamous cell carcinoma. Oral Dis., 2018, 24: 115-119.

[3] Santivasi WL, Xia F. Ionizing radiation-induced DNA damage, response, and repair. Antioxid. Redox Signal., 2014, 21: 251-259.

[4] Feinendegen LE. Reactive oxygen species in cell responses to toxic agents. Hum. Exp. Toxicol., 2002, 21: 85-90.

[5] Surova O, Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene, 2013, 32: 3789-3797.

[6] Su Z, . Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotype. Oncol. Rep., 2016, 36: 72-78.

[7] Ott S, . Radiotherapeutic studies of head and neck cancer-highlights of the 2018 asco annual meeting. HNO, 2018, 66: 901-906.

[8] Russell NS, Bartelink H, Snow GB. Head and neck-cancer. N. Engl. J. Med., 1993, 328: 1783-1784.

[9] Lambrecht M, Dirix P, Van den Bogaert W, Nuyts S. Incidence of isolated regional recurrence after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma. Radiother. Oncol., 2009, 93: 498-502.

[10] Schaaij-Visser TBM, Brakenhoff RH, Leemans CR, Heck AJR, Slijper M. Protein biomarker discovery for head and neck cancer. J. Proteom., 2010, 73: 1790-1803.

[11] Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer, 2004, 101: 2222-2229.

[12] Gold KA, Lee H-Y, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer, 2009, 115: 922-935.

[13] Leon X, . A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol., 2005, 17: 418-424.

[14] Leeman JE, . Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol., 2017, 3: 1487-1494.

[15] Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin. Cancer Biol., 2015, 31: 28-35.

[16] Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv. Drug Deliv. Rev., 2017, 109: 63-73.

[17] Gomez-Casal, R. et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol. Cancer https://doi.org/10.1186/1476-4598-12-94 (2013).

[18] Phillips TM, McBride WH, Pajonk F. The response of CD24(−/low)/CD44(+) breast cancer-initiating cells to radiation. J. Natl Cancer Inst., 2006, 98: 1777-1785.

[19] Piao LS, . CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett., 2012, 315: 129-137.

[20] Lyakhovich A, Lleonart ME. Bypassing mechanisms of mitochondria-mediated cancer stem cells resistance to chemo- and radiotherapy. Oxid. Med. Cell. Longev., 2016

[21] Kurth I, . Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget, 2015, 6: 34494-34509.

[22] Chang L, . Cancer stem cells and signaling pathways in radioresistance. Oncotarget, 2016, 7: 11002-11017.

[23] Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin. Cancer Biol., 2015, 31: 16-27.

[24] Martens-de Kemp SR, . CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res., 2013, 10: 477-488.

[25] Krishnamurthy S, Noer JE. Head and neck cancer stem cells. J. Dent. Res., 2012, 91: 334-340.

[26] Yu C-C, Hu F-W, Yu C-H, Chou M-Y. Targeting CD133 in the enhancement of chemosensitivity in oral squamous cell carcinoma-derived side population cancer stem cells. Head Neck, 2016, 38: E231-E238.

[27] Vermeulen L, . Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol., 2010, 12: 468-U121.

[28] Prince ME, . Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad. Sci. USA, 2007, 104: 973-978.

[29] Misra S, Toole BP, Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem., 2006, 281: 34936-34941.

[30] Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ERBB2 phosphorylation and signaling complex formation in carcinoma cells. J. Biol. Chem., 2005, 280: 8875-8883.

[31] Chen YC, . Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun., 2009, 385: 307-313.

[32] Kim W-T, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep., 2017, 50: 285-298.

[33] Mack, B. & Gires, O. CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE https://doi.org/10.1371/journal.pone.0003360 (2008).

[34] Kaseb HO, Fohrer-Ting H, Lewis DW, Lagasse E, Gollin SM. Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas. Exp. Cell Res., 2016, 348: 75-86.

[35] Han, J., Fujisawa, T., Husain, S. R. & Puri, R. K. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma. BMC Cancer https://doi.org/10.1186/1471-2407-14-173 (2014).

[36] Wang J, . Identification and characterization of CD133(+) CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J. Cancer, 2017, 8: 497-506.

[37] Keysar, S. B. et al. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2. J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djw189 (2017).

[38] Prasmickaite, L. et al. Aldehyde dehydrogenase (aldh) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS ONE https://doi.org/10.1371/journal.pone.0010731 (2010).

[39] Dittfeld C, . CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother. Oncol., 2009, 92: 353-361.

[40] Quintana E, . Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell, 2010, 18: 510-523.

[41] Kim HS, Pearson AT, Nor JE. Isolation and characterization of cancer stem cells from primary head and neck squamous cell carcinoma tumors. Methods Mol. Biol., 2016, 1395: 241-249.

[42] Dontu G, . In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev., 2003, 17: 1253-1270.

[43] Krishnamurthy S, Nor JE. Orosphere assay: a method for propagation of head and neck cancer stem cells. Head Neck, 2013, 35: 1015-1021.

[44] Lim YC, . Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral. Oncol., 2011, 47: 83-91.

[45] Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med., 1996, 183: 1797-1806.

[46] Tabor MH, . Head and neck cancer stem cells: the side population. Laryngoscope, 2011, 121: 527-533.

[47] Loebinger MR, . Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by abc transporter blockade. Br. J. Cancer, 2008, 98: 380-387.

[48] Shen G, . Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell. Dev. Biol. Anim., 2008, 44: 280-289.

[49] Demicheli R, . Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann. Oncol., 2005, 16: 1449-1457.

[50] Kleffel, S. & Schatton, T. in Systems Biology Of Tumor Dormancy Vol. 734 (eds H. Enderling, N. Almog, & L. Hlatky) 145–179 (2013).

[51] Skvortsova I, Debbage P, Kumar V, Slwortsov S. Radiation resistance: cancer stem cells (cscs) and their enigmatic pro-survival signaling. Semin. Cancer Biol., 2015, 35: 39-44.

[52] Arnold CR, . Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis. Oncoscience, 2014, 1: 513-521.

[53] Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene, 2010, 29: 2672-2680.

[54] Hittelman WN, Liao Y, Wang L, Milas L. Are cancer stem cells radioresistant?. Future Oncol., 2010, 6: 1563-1576.

[55] Skvortsov S, . Radioresistant head and neck squamous cell carcinoma cells: Intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother. Oncol., 2011, 101: 177-182.

[56] Lagadec, C. et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. https://doi.org/10.1186/bcr2479 (2010).

[57] Vlashi E, . In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst., 2009, 101: 350-359.

[58] Lee, S. Y. et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol. Cancer https://doi.org/10.1186/s12943-016-0577-4 (2017).

[59] Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol., 2016, 11: 47-76.

[60] Bao S, . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444: 756-760.

[61] Woodward WA, . WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA, 2007, 104: 618-623.

[62] Chaffer CL, . Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA, 2011, 108: 7950-7955.

[63] Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality?. Nat. Med, 2009, 15: 1010-1012.

[64] Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev., 2015, 29: 1203-1217.

[65] Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414: 105-111.

[66] Wang T, . Cancer stem cell targeted therapy: progress amid controversies. Oncotarget, 2015, 6: 44191-44206.

[67] Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. Ionizing radiation induces stemness in cancer cells. PLoS ONE, 2012, 7

[68] Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells, 2012, 30: 833-844.

[69] Salmina K, . Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp. Cell Res., 2010, 316: 2099-2112.

[70] Vlashi E, . Radiation-induced dedifferentiation of head and neck cancer cells into cancer stem cells depends on human papillomavirus status. Int. J. Radiat. Oncol. Biol. Phys., 2016, 94: 1198-1206.

[71] Biswas S, . Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest., 2007, 117: 1305-1313.

[72] Vonessen CF. Radiation enhancement of the metastasis- a review. Clin. Exp. Metastasis, 1991, 9: 77-104.

[73] Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma. Cancer Res., 2001, 61: 2744-2750.

[74] Roman A, . The role of stereotactic body radiotherapy in reirradiation of head and neck cancer recurrence. Crit. Rev. Oncol. Hematol., 2018, 122: 194-201.

[75] Strojan P, . Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. Head Neck, 2015, 37: 134-150.

[76] Chi, H. C., Tsai, C. Y., Tsai, M. M., Yeh, C. T. & Lin, K. H. Roles of long noncoding RNAs in recurrence and metastasis of radiotherapy-resistant cancer stem cells. Int. J. Mol. Sci. https://doi.org/10.3390/ijms18091903 (2017).

[77] Kim BM, . Therapeutic implications for overcoming radiation resistance in cancer therapy. Int. J. Mol. Sci., 2015, 16: 26880-26913.

[78] Liu F, Kong X, Lv L, Gao J. TGF-beta 1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett., 2015, 359: 288-298.

[79] Moncharmont C, . Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett., 2012, 322: 139-147.

[80] Wu L, . TGF-beta 1-induced CK17 enhances cancer stem cell-like properties rather than emt in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway. FEBS J., 2017, 284: 3000-3017.

[81] Beck C, . The kallikrein-kinin-system in head and neck squamous cell carcinoma (hnscc) and its role in tumour survival, invasion, migration and response to radiotherapy. Oral. Oncol., 2012, 48: 1208-1219.

[82] Eke I, Dickreuter E, Cordes N. Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by beta1 integrin inhibition. Radiother. Oncol., 2012, 104: 235-242.

[83] Pickhard, A. C. et al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of egf receptor pathways. BMC Cancer https://doi.org/10.1186/1471-2407-11-388 (2011).

[84] Niwa O, . Icrp publication 131: stem cell biology with respect to carcinogenesis aspects of radiological protection. Ann. ICRP, 2015, 44: 7-357.

[85] Ogawa K, . Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res., 2013, 33: 747-754.

[86] Olive, P. L. In Cytometry, 4th edition: New Developments 75 Methods In Cell Biology (eds. Z. Darzynkiewicz, M. Roederer, & H. Tanke) 355–373 (2004).

[87] Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl Acad. Sci. USA, 2010, 107: 3522-3527.

[88] Yoo YD, Kwon YT. Molecular mechanisms controlling asymmetric and symmetric self-renewal of cancer stem cells. J. Anal. Sci. Technol., 2015, 6: 28-28.

[89] Reid PA, Wilson P, Li Y, Marcu LG, Bezak E. Current understanding of cancer stem cells: Review of their radiobiology and role in head and neck cancers. Head Neck, 2017, 39: 1920-1932.

[90] Gao X, McDonald JT, Hlatky L, Enderling H. Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Res., 2013, 73: 1481-1490.

[91] Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase htert in cancer stemness and metastasis. FEBS Lett., 2018, 592: 2023-2031.

[92] Liu Z, . Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene, 2013, 32: 4203-4213.

[93] Park J-I, . Telomerase modulates Wnt signalling by association with target gene chromatin. Nature, 2009, 460: 66-U77.

[94] Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol., 2014, 15: 178-196.

[95] Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev., 2013, 27: 2192-2206.

[96] De Craene B, Berx G. Regulatory networks defining emt during cancer initiation and progression. Nat. Rev. Cancer, 2013, 13: 97-110.

[97] Wozny, A. S. et al. Ros production and distribution: a new paradigm to explain the differential effects of x-ray and carbon ion irradiation on cancer stem cell migration and invasion. Cancers https://doi.org/10.3390/cancers11040468 (2019).

[98] De Bacco F, . Induction of met by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl Cancer Inst., 2011, 103: 645-661.

[99] Kawamoto A, . Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol. Rep., 2012, 27: 51-57.

[100] Moncharmont C, . Radiation-enhanced cell migration/invasion process: a review. Crit. Rev. Oncol. Hematol., 2014, 92: 133-142.

[101] Zhang X, Li XY, Zhang N, Yang QF, Moran MS. Low doses ionizing radiation enhances the invasiveness of breast cancer cells by inducing epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun., 2011, 412: 188-192.

[102] Martin M, . Coactivation of AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene, 1997, 15: 981-989.

[103] O’Malley YX, Zhao WL, Barcellos-Hoff MH, Robbins MEC. Radiation-induced alterations in rat mesangial cell Tgfb1 and Tgfb3 gene expression are not associated with altered secretion of active Tgfb isoforms. Radiat. Res., 1999, 152: 622-628.

[104] Luo J, . Smad7 promotes healing of radiotherapy-induced oral mucositis without compromising oral cancer therapy in a xenograft mouse model. Clin. Cancer Res., 2019, 25: 808-818.

[105] Li K, . TGF beta induces sternness through non-canonical AKT-FOXO3A axis in oral squamous cell carcinoma. Ebiomedicine, 2019, 48: 70-80.

[106] Zhang K-H, . Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition. Cancer Res., 2009, 69: 5340-5348.

[107] Zhao H, . Up-regulation of glycolysis promotes the stemness and emt phenotypes in gemcitabine-resistant pancreatic cancer cells. J. Cell. Mol. Med., 2017, 21: 2055-2067.

[108] Cannito S, . Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis, 2008, 29: 2267-2278.

[109] Jin Y, . Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: Inactivation of the NF-kappa b pathway and generation of reactive oxygen species. Cancer Res., 2010, 70: 2516-2527.

[110] Radisky DC, . Rac1b and reactive oxygen species mediate MMP-3-induced emt and genomic instability. Nature, 2005, 436: 123-127.

[111] Moore KA, Lemischka IR. Stem cells and their niches. Science, 2006, 311: 1880-1885.

[112] Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell, 2007, 1: 607-611.

[113] LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res., 2010, 16: 3121-3129.

[114] Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell, 2014, 14: 306-321.

[115] Krishnamurthy S, . Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells, 2014, 32: 2845-2857.

[116] Kuonen F, Secondini C, Rueegg C. Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin. Cancer Res., 2012, 18: 5196-5202.

[117] Zhang M, . Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma. Cancer, 2014, 120: 992-1001.

[118] Charles N, . Perivascular nitric oxide activates notch signaling and promotes stem-like character in pdgf-induced glioma cells. Cell Stem Cell, 2010, 6: 141-152.

[119] Kim, S. D. et al. The malignancy of liver cancer cells is increased by IL-4/erk/akt signaling axis activity triggered by irradiated endothelial cells. J. Radiat. Res. https://doi.org/10.1093/jrr/rraa002 (2020).

[120] Krishnamurthy S, . Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res., 2010, 70: 9969-9978.

[121] Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. Cancer stem cells as a predictive factor in radiotherapy. Semin. Radiat. Oncol., 2012, 22: 151-174.

[122] Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother. Oncol., 2013, 108: 378-387.

[123] Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer, 2006, 6: 392-401.

[124] Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (cafs) in tumor microenvironment. Front. Biosci. Landmark, 2010, 15: 166-179.

[125] Hu, Y. et al. Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer. PLoS ONE https://doi.org/10.1371/journal.pone.0125625 (2015).

[126] Wu, F. et al. Regulation of proliferation and cell cycle by protein regulator of cytokinesis 1 in oral squamous cell carcinoma. Cell Death Dis. https://doi.org/10.1038/s41419-018-0618-6 (2018).

[127] Meng W, . A systems biology approach identifies effective tumor-stroma common targets for oral squamous cell carcinoma. Cancer Res., 2014, 74: 2306-2315.

[128] Chen WJ, . Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun., 2014, 5

[129] Li D, . Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Am. J. Cancer Res., 2016, 6: 2192-+.

[130] Tommelein J, . Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res., 2018, 78: 659-670.

[131] Zhou L-Y, Wang Z-M, Gao Y-B, Wang L-Y, Zeng Z-C. Stimulation of hepatoma cell invasiveness and metastatic potential by proteins secreted from irradiated nonparenchymal cells. Int. J. Radiat. Oncol. Biol. Phys., 2012, 84: 822-828.

[132] Chargari C, Clemenson C, Martins I, Perfettini JL, Deutsch E. Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation. Drug Resist. Updates, 2013, 16: 10-21.

[133] Kamochi N, . Irradiated fibroblast-induced bystander effects on invasive growth of squamous cell carcinoma under cancer-stromal cell interaction. Cancer Sci., 2008, 99: 2417-2427.

[134] Bouchard G, . Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. Br. J. Cancer, 2013, 109: 1829-1838.

[135] Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 2006, 124: 263-266.

[136] Kozin SV, . Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res., 2010, 70: 5679-5685.

[137] Russell, J. S. & Brown, J. M. The irradiated tumor microenvironment: Role of tumor-associated macrophages in vascular recovery. Front. Physiol. https://doi.org/10.3389/fphys.2013.00157 (2013).

[138] Ye X-z, . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta 1 signaling pathway. J. Immunol., 2012, 189: 444-453.

[139] Jinushi M, . Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl Acad. Sci. USA, 2011, 108: 12425-12430.

[140] Brown JM. The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain Memorial award lecture. Cancer Res., 1999, 59: 5863-5870.

[141] Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev., 2007, 26: 319-331.

[142] Das B, . Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells, 2008, 26: 1818-1830.

[143] Moeller BJ, . Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 2005, 8: 99-110.

[144] Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev., 2007, 26: 241-248.

[145] Yeung TM, Gandhi SC, Bodmer WF. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc. Natl Acad. Sci. USA, 2011, 108: 4382-4387.

[146] Wozny AS, . Differential pattern of HIF-1 alpha expression in hnscc cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect. Br. J. Cancer, 2017, 116: 1340-1349.

[147] Hall, E. J. & Giaccia, A. J. Radiobiology for the radiologist. Vol. 6 (Lippincott Williams & Wilkins, 2006).

[148] Diehn M, . Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 2009, 458: 780-783.

[149] Li L, . Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology, 2014, 146: 1108-U1361.

[150] Gurtner K, . Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother. Oncol., 2012, 102: 444-449.

[151] Tijink BM, . A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res., 2006, 12: 6064-6072.

[152] Leung C, . Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature, 2004, 428: 337-341.

[153] Facchino S, Abdouh M, Chatoo W, Bernier G. Bmi1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J. Neurosci., 2010, 30: 10096-10111.

[154] Xu X-H, . ShRNA targeting Bmi-1 sensitizes CD44(+) nasopharyngeal cancer stem-like cells to radiotherapy. Oncol. Rep., 2014, 32: 764-770.

[155] Kreso A, . Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med., 2014, 20: 29-36.

[156] Hu J, . Cancer stem cell self-renewal as a therapeutic target in human oral cancer. Oncogene, 2019, 38: 5440-5456.

[157] Du, B. & Shim, J. S. Targeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancer. Molecules https://doi.org/10.3390/molecules21070965 (2016).

[158] Feng X, Lv W, Wang S, He Q. miR495 enhances the efficacy of radiotherapy by targeting grp78 to regulate emt in nasopharyngeal carcinoma cells. Oncol. Rep., 2018, 40: 1223-1232.

[159] Wu X, . Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget, 2016, 7: 11708-11723.

[160] Zhao, Z. et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS ONE https://doi.org/10.1371/journal.pone.0095884 (2014).

[161] Vazquez-Martin A, . Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (emt) status. Cell Cycle, 2010, 9: 3807-3814.

[162] Qu C, . Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Mol. Cell. Biochem., 2014, 386: 63-71.

[163] Zannella VE, . Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res., 2013, 19: 6741-6750.

[164] Ferro A, . Evaluation of diabetic patients with breast cancer treated with metformin during adjuvant radiotherapy. Int. J. Breast Cancer, 2013, 2013: 659723-659723.

[165] Spratt DE, . Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur. Urol., 2013, 63: 709-716.

[166] Wu X, . Metformin inhibits progression of head and neck squamous cell carcinoma by acting directly on carcinoma-initiating cells. Cancer Res., 2019, 79: 4360-4370.

[167] Siddappa G, . Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells. Mol. Carcinog., 2017, 56: 2446-2460.

[168] Calabrese C, . A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11: 69-82.

[169] Yang ZJ, Wechsler-Reya RJ. Hit ‘em where they live: targeting the cancer stem cell niche. Cancer Cell, 2007, 11: 3-5.

[170] Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer, 2005, 5: 744-749.

[171] Kamlah F, . Comparison of the effects of carbon ion and photo irradiation on the angiogenic response in human lung adenocarcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80: 1541-1549.

Funding

National Nature Science Foundation of China (No. 81772898); Scientific Research Foundation of Sichuan Province, China (No. 2019YFH0082)